PPIB and cancer: While a number of studies indicate that Glatiramer Acetate and Interferon-β do not raise the overall risk of cancer, it has been proposed that immunosuppressive drugs such as cladribine, fingolimod, natalizumab, and alemtuzumab may carry a potential cancer risk due to their action on the immune system and the lack of long-term data [6].